Par Pharm Company Profile
✉ Email this page to a colleague
What is the competitive landscape for PAR PHARM, and when can generic versions of PAR PHARM drugs launch?
PAR PHARM has one hundred and fifty-three approved drugs.
There is one US patent protecting PAR PHARM drugs. There are thirteen tentative approvals on PAR PHARM drugs.
There are nine patent family members on PAR PHARM drugs in eight countries and one hundred and ninety supplementary protection certificates in fifteen countries.
Summary for Par Pharm
| International Patents: | 9 |
| US Patents: | 1 |
| Tradenames: | 98 |
| Ingredients: | 96 |
| NDAs: | 153 |
| Patent Litigation for Par Pharm: | See patent lawsuits for Par Pharm |
| PTAB Cases with Par Pharm as petitioner: | See PTAB cases with Par Pharm as petitioner |
Drugs and US Patents for Par Pharm
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Par Pharm | OLANZAPINE AND FLUOXETINE HYDROCHLORIDE | fluoxetine hydrochloride; olanzapine | CAPSULE;ORAL | 077742-004 | Nov 2, 2012 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Par Pharm | CHLORPROPAMIDE | chlorpropamide | TABLET;ORAL | 088176-001 | Feb 27, 1984 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Par Pharm | CLONAZEPAM | clonazepam | TABLET, ORALLY DISINTEGRATING;ORAL | 077171-001 | Aug 3, 2005 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Par Pharm | EVEROLIMUS | everolimus | TABLET;ORAL | 207934-003 | Dec 9, 2019 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Par Pharm | FENTANYL CITRATE | fentanyl citrate | TROCHE/LOZENGE;TRANSMUCOSAL | 077312-002 | Oct 30, 2009 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Par Pharm | HALOPERIDOL | haloperidol | TABLET;ORAL | 071328-001 | Jul 20, 1987 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Par Pharm
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Par Pharm | NASCOBAL | cyanocobalamin | GEL, METERED;NASAL | 019722-001 | Nov 5, 1996 | 4,724,231 | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for PAR PHARM drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Nasal Spray | 500 mcg/spray | ➤ Subscribe | 2017-04-28 |
International Patents for Par Pharm Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 2605413 | ⤷ Try a Trial |
| China | 101163679 | ⤷ Try a Trial |
| World Intellectual Property Organization (WIPO) | 2006115626 | ⤷ Try a Trial |
| European Patent Office | 1948613 | ⤷ Try a Trial |
| South Korea | 20080000660 | ⤷ Try a Trial |
| Australia | 2006240490 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Par Pharm Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0785926 | SPC/GB08/047 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: AMBRISENTAN; REGISTERED: UK EU/1/08/451/001 20080421; UK EU/1/08/451/002 20080421; UK EU/1/08/451/003 20080421; UK EU/1/08/451/004 20080421 |
| 2330892 | 2016/064 | Ireland | ⤷ Try a Trial | PRODUCT NAME: GLYCEROL PHENYLBUTYRATE; REGISTRATION NO/DATE: EU/1/15/1062 20151201 |
| 2203431 | 1590018-6 | Sweden | ⤷ Try a Trial | PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150119 |
| 2269603 | PA2015041 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: EVEROLIMUSUM; REGISTRATION NO/DATE: EU/1/09/538/001, EU/1/09/538/003, EU/1/09/538/004, EU/1/09/538/006-010 20120723 |
| 2822954 | SPC/GB18/031 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM.; REGISTERED: UK EU/1/18/1289/001(NI) 20180625; UK EU/1/18/1289/002(NI) 20180625; UK PLGB 11972/0008 20180625 |
| 2269604 | 93320 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: EVEROLIMUS OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/09/538-001-006 - AFINITOR - EVEROLIMUS |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
